Medication info
Janurodi Tablets 100 Milligrams (Sitagliptin Hydrochloride Hydrate)

Janurodi Tablets 100 Milligrams (Sitagliptin Hydrochloride Hydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.4mg / 1 tablet
Manufacturer / importer
Kwangdong Pharmaceutical Co., Ltd.
Appearance
Light orange, round, biconvex film-coated tablet
Packaging
30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 202004048 · Approved 2020.05.29 · Insurance code 641807070

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
Administer 100 mg once daily as monotherapy or combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When this medicine is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Assessment of renal function before starting treatment with this medicine and periodically thereafter is recommended, as dosage adjustment is required according to renal function. 1. No dosage adjustment is required in patients with mild renal impairment (eGFR ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (eGFR ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (eGFR ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.

Ingredients

Manufacturer
Kwangdong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood glucose control in patients with type 2 diabetes
View approved original text

This medication is used to improve blood glucose control in patients with type 2 diabetes. It can be administered alone or in combination with dietary and exercise therapy and can be used in patients with no previous experience with other diabetes medications. If blood glucose control is insufficient with monotherapy, it can be administered in combination with metformin. Furthermore, if blood glucose control is difficult with monotherapy using sulfonylurea, metformin, thiazolidinedione, or insulin, this medication can be combined with other agents to enhance effectiveness. Even when blood glucose control is challenging with multiple medications, this drug can be added to continue treatment. This medication is effectively used to improve blood glucose control.

How to take

Adult dose

Administer 100 mg once daily as monotherapy or combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When this medicine is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Assessment of renal function before starting treatment with this medicine and periodically thereafter is recommended, as dosage adjustment is required according to renal function. 1. No dosage adjustment is required in patients with mild renal impairment (eGFR ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (eGFR ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (eGFR ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.

Precautions

This medication may cause severe allergic reactions after administration. If symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur, discontinue use immediately and consult a doctor. This drug may cause serious inflammation of the pancreas, known as pancreatitis. Inform medical personnel immediately if symptoms such as abdominal pain, vomiting, or nausea appear. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, nor in patients with hypersensitivity to the drug. Patients with impaired kidney function should have their dosage adjusted; those with kidney disease must consult a doctor. While taking this medication, hypoglycemic symptoms may occur, especially if taken with insulin or sulfonylurea, so blood glucose should be monitored closely, and the dosage of other medications should be adjusted if necessary. Severe joint pain or skin blistering may occur; contact medical personnel immediately if these symptoms arise. Use of this medication during pregnancy or breastfeeding is not recommended, and safety and efficacy have not been established in individuals under 18 years of age. In older adults, kidney function may be impaired, so kidney function tests are needed before and after administration. In cases of overdose, gastrointestinal removal of the drug and appropriate treatments like ECG monitoring may be necessary, and some may be removed by dialysis. This medication has low drug interaction potential, but caution is needed when used in combination with cyclosporine or digoxin; inform your doctor.

Side effects

  • Hypersensitivity
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • exfoliative skin disease
  • acute pancreatitis
  • hypoglycemia
  • upper respiratory tract infection
  • nasopharyngitis
  • headache
Show 29 more
  • diarrhea
  • abdominal pain
  • nausea
  • constipation
  • vomiting
  • severe arthralgia with disability
  • blistering similar to pemphigus
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevation of liver enzymes
  • acute renal failure
  • pneumonia
  • diabetic complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • indigestion
  • dizziness
  • increased blood triglycerides
  • gastritis
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. It is advisable to maintain a storage temperature between 1 degrees and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Light orange, round, biconvex film-coated tablet

Package unit

30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.